161 related articles for article (PubMed ID: 16355273)
1. CCR1 acts downstream of NFAT2 in osteoclastogenesis and enhances cell migration.
Ishida N; Hayashi K; Hattori A; Yogo K; Kimura T; Takeya T
J Bone Miner Res; 2006 Jan; 21(1):48-57. PubMed ID: 16355273
[TBL] [Abstract][Full Text] [Related]
2. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
3. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
[TBL] [Abstract][Full Text] [Related]
4. CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts.
Lean JM; Murphy C; Fuller K; Chambers TJ
J Cell Biochem; 2002; 87(4):386-93. PubMed ID: 12397598
[TBL] [Abstract][Full Text] [Related]
5. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
[TBL] [Abstract][Full Text] [Related]
7. Expression profile of RhoGTPases and RhoGEFs during RANKL-stimulated osteoclastogenesis: identification of essential genes in osteoclasts.
Brazier H; Stephens S; Ory S; Fort P; Morrison N; Blangy A
J Bone Miner Res; 2006 Sep; 21(9):1387-98. PubMed ID: 16939397
[TBL] [Abstract][Full Text] [Related]
8. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
10. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
11. RANKL treatment releases the negative regulation of the poly(ADP-ribose) polymerase-1 on Tcirg1 gene expression during osteoclastogenesis.
Beranger GE; Momier D; Rochet N; Quincey D; Guigonis JM; Samson M; Carle GF; Scimeca JC
J Bone Miner Res; 2006 Nov; 21(11):1757-69. PubMed ID: 17002555
[TBL] [Abstract][Full Text] [Related]
12. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2003 Aug; 18(8):1404-18. PubMed ID: 12929930
[TBL] [Abstract][Full Text] [Related]
13. Induction of DC-STAMP by alternative activation and downstream signaling mechanisms.
Yagi M; Ninomiya K; Fujita N; Suzuki T; Iwasaki R; Morita K; Hosogane N; Matsuo K; Toyama Y; Suda T; Miyamoto T
J Bone Miner Res; 2007 Jul; 22(7):992-1001. PubMed ID: 17402846
[TBL] [Abstract][Full Text] [Related]
14. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
O'Sullivan S; Naot D; Callon K; Porteous F; Horne A; Wattie D; Watson M; Cornish J; Browett P; Grey A
J Bone Miner Res; 2007 Nov; 22(11):1679-89. PubMed ID: 17663639
[TBL] [Abstract][Full Text] [Related]
15. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
16. Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand.
Balkan W; Martinez AF; Fernandez I; Rodriguez MA; Pang M; Troen BR
Gene; 2009 Oct; 446(2):90-8. PubMed ID: 19563866
[TBL] [Abstract][Full Text] [Related]
17. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
Kondo H; Guo J; Bringhurst FR
J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
19. The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells.
Egusa H; Doi M; Saeki M; Fukuyasu S; Akashi Y; Yokota Y; Yatani H; Kamisaki Y
Bone; 2011 Aug; 49(2):264-74. PubMed ID: 21504804
[TBL] [Abstract][Full Text] [Related]
20. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
